OmniAb, Inc. (OABI) Research

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

Market snapshot

Symbol
OABI
Price
$2.34
Day change
+15.27%
Market cap
$278.7M
P/E ratio
-5.53x
52-week range
1.3-2.79
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$4.00

Peer companies

  • Armata Pharmaceuticals, Inc. (ARMP)
  • C4 Therapeutics, Inc. (CCCC)
  • Codexis, Inc. (CDXS)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • Innate Pharma S.A. (IPHA)
  • Invivyd, Inc. (IVVD)
  • Milestone Pharmaceuticals Inc. (MIST)
  • Rani Therapeutics Holdings, Inc. (RANI)

Recent insider activity

  • Bertozzi Carolyn R — M-Exempt (20000 shares) on 2026-06-17
  • Bertozzi Carolyn R — A-Award (40000 shares) on 2026-06-17
  • Bertozzi Carolyn R — A-Award (20000 shares) on 2026-06-17
  • Bertozzi Carolyn R — M-Exempt (20000 shares) on 2026-06-17
  • Cochran Jennifer R. — M-Exempt (20000 shares) on 2026-06-17

Open OmniAb, Inc. (OABI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.